Nuveen Asset Management, LLC Xeris Biopharma Holdings, Inc. Transaction History

Nuveen Asset Management, LLC

$340 Billion
Q4 2024

A detailed history of Nuveen Asset Management, LLC transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 1,903,442 shares of XERS stock, worth $9.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,903,442

Previous 1,675,062 13.63%

Holding current value

$9.23 Million

Previous $4.77 Million 35.18%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.78 - $3.73 $634,896 - $851,857	228,380 Added 13.63%	1,903,442 $6.45 Million
Q3 2024 Nov 14, 2024	BUY	$2.06 - $2.96 $684,847 - $984,052	332,450 Added 24.76%	1,675,062 $4.77 Million
Q2 2024 Aug 09, 2024	SELL	$1.7 - $2.45 $421,413 - $607,330	-247,890 Reduced 15.59%	1,342,612 $3.02 Million
Q1 2024 May 13, 2024	BUY	$2.04 - $3.22 $2.38 Million - $3.75 Million	1,165,530 Added 274.26%	1,590,502 $3.52 Million
Q4 2023 Feb 14, 2024	SELL	$1.47 - $2.36 $422,955 - $679,031	-287,725 Reduced 40.37%	424,972 $998,000
Q3 2023 Nov 14, 2023	BUY	$1.8 - $2.69 $527,634 - $788,519	293,130 Added 69.86%	712,697 $1.33 Million
Q2 2023 Aug 14, 2023	SELL	$1.82 - $2.98 $3,365 - $5,510	-1,849 Reduced 0.44%	419,567 $1.1 Million
Q1 2023 May 15, 2023	SELL	$1.03 - $1.63 $5,567 - $8,810	-5,405 Reduced 1.27%	421,416 $686,000
Q4 2022 Feb 14, 2023	SELL	$1.14 - $1.65 $26,632 - $38,547	-23,362 Reduced 5.19%	426,821 $567,000
Q3 2022 Nov 14, 2022	BUY	$1.37 - $1.93 $7,204 - $10,149	5,259 Added 1.18%	450,183 $702,000
Q2 2022 Aug 15, 2022	BUY	$1.48 - $2.64 $658,487 - $1.17 Million	444,924 New	444,924 $685,000

Others Institutions Holding XERS

# of Institutions

204

Shares Held

84.7M

Call Options Held

132K

Put Options Held

69.4K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $659M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account

Nuveen Asset Management, LLC Xeris Biopharma Holdings, Inc. Transaction History